A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 02 May 2018 Status changed from not yet recruiting to recruiting.
- 16 Mar 2018 Planned initiation date changed from 6 Mar 2018 to 6 Apr 2018.